×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 9: Hot Topics
Session Chair(s)
Arthur A. Levin, PhD
Distinguished Scientist
Avidity Biosciences, United States
Emily Place, PhD, MPH
Senior Consultant
Aclairo Pharmaceutical Development Group, United States
Attendees at this session will hear about novel technologies that are bridging the gap between early research and clinical development. Each is an area that holds the promise of creating a new platform for oligonucleotide therapeutics. Featured in this session are:
- A novel delivery platform using a conjugate approach
- Circular RNAs as potential therapeutics
- A novel and personalized aptamer technology in oncology
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss insights into the promise of these technologies and how these technologies have the potential for broad applications
- Explore where the oligonucleotide therapeutics field will advance in the future
Speaker(s)
AUMMUNE Therapy Driven by Effect
Irit Carmi-Levy, PhD
Aummune, Israel
Chief Scientific Officer and Vice President R&D
A Novel Antibody Platform for Nucleic Acid Delivery with Broad Therapeutic Potential
Chris Duke, MBA, MPH
Gennao Bio, United States
Cheif Operating Officer
The Therapeutic Potential of oRNA
Robert Mabry, PhD
Orna Therapeutics, Inc. , United States
Chief Scientific Officer
Have an account?